Anti-CD19 chimeric antigen receptor T cell therapy - Chongqing Precision Biotech
Alternative Names: Anti-CD19 CAR-T cell therapy-Chongqing Precision BiotechLatest Information Update: 29 Aug 2024
At a glance
- Originator Chongqing Precision Biotech Co., Ltd
- Class Anti-inflammatories; CAR-T cell therapies; Gene therapies; Skin disorder therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Anti-neutrophil cytoplasmic antibody-associated vasculitis; Dermatomyositis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Most Recent Events
- 02 Jul 2024 Phase-I clinical trials in Dermatomyositis (In children, In adolescents) in China (IV) (NCT06569472)
- 04 Jan 2024 Phase-I clinical trials in Systemic lupus erythematosus (In children, In adolescents) in China (IV) (NCT06222853)
- 31 Aug 2023 Phase-I clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis in China (IV) (NCT06056921)